Skip to main content
TipRanks
Go Ultimate75% OFF

CG Oncology, Inc. (CGON) AI Stock Analysis

378 Followers
CGON

CG Oncology, Inc.

(NASDAQ:CGON)

Select Model
Rating:68Neutral
Price Target:$92.00â–²(16.54% Upside)
Action:reiterated
Date:11/17/26

The score is driven by strong technical momentum and a highly positive Phase 3 trial catalyst, supported by a low-debt balance sheet. These positives are tempered by very weak current financial performance, including collapsing revenue, large operating losses, and substantial ongoing cash burn, while valuation inputs are limited due to negative earnings and no dividend yield.

Positive Factors
Phase 3 efficacyThe pivotal trial’s statistically significant recurrence reduction provides strong clinical validation for cretostimogene and could support regulatory progress. Durable efficacy in a registrational setting may improve the product’s ability to gain adoption and establish a meaningful position in bladder cancer.
Negative Factors
Limited commercial scaleMinimal and sharply contracting revenue shows that CG Oncology has not yet demonstrated durable commercial scale. Until its clinical candidate reaches broader commercialization, the company remains exposed to highly volatile revenue and must rely primarily on development progress rather than recurring product sales.

CG Oncology, Inc. (CGON) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%CGON+93.91%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.05B
Dividend Yield
―
Average Volume (3M)
1.18M
Price to Earnings (P/E)
-28.4
Beta (1Y)
1.56
Revenue Growth
183.62%
EPS Growth
-39.33%
Country
US
Employees
142
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigationa...

CG Oncology, Inc. Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is a clear strength with very low leverage (debt-to-equity ~0.009) and substantial assets/equity, but operating performance is weak: TTM revenue is small ($6.2M) and sharply down (-99.6% growth), profitability is deeply negative (TTM EBIT -$264.7M; net loss -$180.6M), and cash flow shows heavy burn (TTM FCF -$189.2M).

Income Statement

12Very Negative

Balance Sheet

74Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.17M4.04M1.14M204.00K191.00K10.36M
Gross Profit-6.30M-607.00K-80.96M-45.55M176.00K10.35M
EBITDA-233.76M-159.55M-88.01M-48.59M-35.43M-12.38M
Net Income-237.46M-161.00M-88.04M-48.61M-35.44M-12.84M
Balance Sheet
Total Assets1.05B791.59M754.80M199.30M147.75M58.69M
Cash, Cash Equivalents and Short-Term Investments984.46M742.15M742.00M187.67M143.48M53.61M
Total Debt9.24M7.02M238.00K1.03M15.94M15.13M
Total Liabilities55.70M38.99M21.42M14.51M22.57M18.44M
Stockholders Equity990.97M752.60M733.38M184.79M125.18M40.25M
Cash Flow
Free Cash Flow-189.17M-132.48M-78.95M-45.68M-29.82M-13.75M
Operating Cash Flow-187.28M-132.35M-78.71M-45.68M-29.80M-13.65M
Investing Cash Flow-333.89M-245.82M-300.76M-121.19M-55.35M-97.00K
Financing Cash Flow504.27M153.59M628.28M87.00M119.69M15.45M

CG Oncology, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price78.94

Price Trends

50DMA68.35Positive
100DMA71.02Positive
200DMA66.96Positive

Market Momentum

MACD3.26Negative
RSI61.68Neutral
STOCH62.66Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 78.94 is above the 20-day moving average (MA) of 68.29, above the 50-day MA of 68.35, and above the 200-day MA of 66.96, indicating a bullish trend. The MACD of 3.26 indicates Negative momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 62.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.

CG Oncology, Inc. Risk Analysis

CG Oncology, Inc. disclosed 82 risk factors in its most recent earnings report. CG Oncology, Inc. reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

CG Oncology, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CGON against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CGONCGON68Neutral$7.05B-28.36-24.58%―183.62%-39.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ERASERAS49Neutral$4.87B-14.04-61.67%――-120.99%
COGTCOGT45Neutral$4.85B-12.01-71.13%――0.71%
ORICORIC44Neutral$831.45M-5.35-40.99%――15.37%
RLAYRLAY44Neutral$3.64B-10.95-40.25%―23.86%13.76%
TNGXTNGX41Neutral$3.75B-16.17-30.34%―-100.00%-49.92%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%CGONCOGTORICRLAYTNGXERASDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CGON and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CGONCG Oncology, Inc.78.9436.3485.31%
COGTCogent Biosciences, Inc.27.85-7.09-20.29%
ORICOric Pharmaceuticals Inc8.00-3.48-30.31%
RLAYRelay Therapeutics Inc16.4710.13159.78%
TNGXTango Therapeutics, Inc.22.1113.83167.03%
ERASErasca, Inc.13.8911.13403.26%

CG Oncology, Inc. Corporate Events

Product-Related Announcements

CG Oncology Reports Positive Phase 3 Bladder Cancer Trial Results

Positive
Nov 16, 2026

On November 16, 2026, CG Oncology announced topline results from its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer following comp...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026